The goal of this clinical research study is to find the highest tolerable dose of OPB-31121
that can be given to patients with an advanced solid tumor. The safety of this drug will also
be studied.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Otsuka Pharmaceutical Development & Commercialization, Inc.